MedPath

Evaluation of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.

Not Applicable
Completed
Conditions
Metastatic colorectal cancer treated with FOLFOXIRI
Cancer - Bowel - Back passage (rectum) or large bowel (colon)
Registration Number
ACTRN12608000615381
Lead Sponsor
Gruppo Oncologico del Nord-Ovest GONO
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
37
Inclusion Criteria

Metastatic colorectal cancer;
Unresectable disease at diagnosis;
First-line treatment with FOLFOXIRI

Exclusion Criteria

Treatment with chemotherapy different from FOLFOXIRI;
Eastern Cooperative Oncology Group (ECOG) Performance status (PS) >2

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath